Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
GeNeuro SA GNRO.PA
$1.82
+$0.13 (7.06%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
46526960.00000000
-
week52high
3.48
-
week52low
1.30
-
Revenue
0
-
P/E TTM
-5
-
Beta
0.32366400
-
EPS
-0.38000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 апр 2023 г. в 10:59
Описание компании
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Свежие комментарии
Свежие комментарии